Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1671-1680 of 1,873) with videos related to

Pageof 188
Sort By:
European Journal of Heart Failure|November 7, 2023
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trialMorten Schou, Brian Claggett, Zi Michael Miao, et al.
Circulation. Heart Failure|September 29, 2024
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HFMisato Chimura, Mark C Petrie, Morten Schou, et al.
JACC. Heart Failure|June 9, 2023
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy StatusAlexander Peikert, Parag Goyal, Muthiah Vaduganathan, et al.
JAMA Cardiology|November 17, 2024
Electronic Nudges and Influenza Vaccination Among Patients With a History of Myocardial Infarction: Insights From 3 Nationwide Randomized Clinical TrialsAnkeet S Bhatt, Niklas Dyrby Johansen, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|April 11, 2026
Effects of Finerenone Across a Range of Heart Failure Duration: A Prespecified Analysis of the FINEARTS-HF TrialYasuhiro Hamatani, John W Ostrominski, Henri Lu, et al.
Journal of the American College of Cardiology|July 5, 2023
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart FailureKieran F Docherty, Kirsty McDowell, Paul Welsh, et al.
JACC. Heart Failure|February 7, 2021
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HFLi Shen, Søren Lund Kristensen, Olof Bengtsson, et al.
Journal of the American College of Cardiology|May 30, 2020
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic CardiomyopathyCarolyn Y Ho, Matthew E Mealiffe, Richard G Bach, et al.
European Journal of Heart Failure|February 23, 2021
Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trialNinian N Lang, Faheem A Ahmad, John G Cleland, et al.
JAMA Cardiology|November 3, 2022
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.
Pageof 188

Showing results (1671-1680 of 1,873) with videos related to

Sort By:
Pageof 188
European Journal of Heart Failure|November 7, 2023
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trialMorten Schou, Brian Claggett, Zi Michael Miao, et al.
Circulation. Heart Failure|September 29, 2024
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HFMisato Chimura, Mark C Petrie, Morten Schou, et al.
JACC. Heart Failure|June 9, 2023
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy StatusAlexander Peikert, Parag Goyal, Muthiah Vaduganathan, et al.
JAMA Cardiology|November 17, 2024
Electronic Nudges and Influenza Vaccination Among Patients With a History of Myocardial Infarction: Insights From 3 Nationwide Randomized Clinical TrialsAnkeet S Bhatt, Niklas Dyrby Johansen, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|April 11, 2026
Effects of Finerenone Across a Range of Heart Failure Duration: A Prespecified Analysis of the FINEARTS-HF TrialYasuhiro Hamatani, John W Ostrominski, Henri Lu, et al.
Journal of the American College of Cardiology|July 5, 2023
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart FailureKieran F Docherty, Kirsty McDowell, Paul Welsh, et al.
JACC. Heart Failure|February 7, 2021
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HFLi Shen, Søren Lund Kristensen, Olof Bengtsson, et al.
Journal of the American College of Cardiology|May 30, 2020
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic CardiomyopathyCarolyn Y Ho, Matthew E Mealiffe, Richard G Bach, et al.
European Journal of Heart Failure|February 23, 2021
Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trialNinian N Lang, Faheem A Ahmad, John G Cleland, et al.
JAMA Cardiology|November 3, 2022
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.
Pageof 188